Shabir Madhi to Half-Life
This is a "connection" page, showing publications Shabir Madhi has written about Half-Life.
Connection Strength
0,245
-
A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants. J Infect Dis. 2025 Mar 17; 231(3):e478-e487.
Score: 0,245